
NextPlat Corp. (NASDAQ:NXPL – Free Report) – Stock analysts at Litchfield Hills Research upped their Q1 2027 earnings estimates for shares of NextPlat in a note issued to investors on Monday, August 17th. Litchfield Hills Research analyst T. O’neill now anticipates that the company will post earnings of $0.11 per share for the quarter, up from their prior forecast of $0.10. Litchfield Hills Research currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for NextPlat’s current full-year earnings is ($0.55) per share. Litchfield Hills Research also issued estimates for NextPlat’s Q2 2027 earnings at $0.16 EPS and FY2027 earnings at $0.61 EPS.
NextPlat (NASDAQ:NXPL – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.16. The business had revenue of $11.88 million during the quarter, compared to analyst estimates of $11.00 million. NextPlat had a negative net margin of 20.38% and a negative return on equity of 53.16%.
Read Our Latest Stock Analysis on NextPlat
NextPlat Trading Down 4.6%
NextPlat stock opened at $8.07 on Wednesday. The firm has a market cap of $21.85 million, a price-to-earnings ratio of -2.20 and a beta of 1.83. NextPlat has a 1 year low of $3.38 and a 1 year high of $11.10. The firm’s 50 day moving average price is $6.50 and its two-hundred day moving average price is $5.98. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.12 and a current ratio of 2.56.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in NextPlat stock. Citadel Advisors LLC purchased a new stake in shares of NextPlat Corp. (NASDAQ:NXPL – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned 0.19% of NextPlat at the end of the most recent reporting period. Institutional investors and hedge funds own 1.30% of the company’s stock.
About NextPlat
NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.
Further Reading
- Five stocks we like better than NextPlat
- Amazon Plugs $18B Into the Southern Power Grid
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
Receive News & Ratings for NextPlat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextPlat and related companies with MarketBeat.com's FREE daily email newsletter.
